Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 1, 2008, Pages 68-74

  Economopoulos, Theofanis ^a   Psyrri, Amanda ^a   Fountzilas, George ^b   Tsatalas, Constantinos ^c   Anagnostopoulos, Athanasios ^d   Papageorgiou, Sotirios ^a   Xiros, Nikolaos ^a   Dimopoulos, Meletios Athanasios ^d  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b Papageorgiou University Hospital   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d ALEXANDRA HOSPITAL   (Greece)

Author keywords

Chemotherapy; Low grade NHL; Rituximab

Indexed keywords

FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; RITUXIMAB;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS B; HUMAN; INFECTION; LEUKEMIA REMISSION; LEUKOPENIA; MALE; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MITOXANTRONE; REMISSION INDUCTION; TREATMENT OUTCOME; VIDARABINE;

EID: 38649103157     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701784714     Document Type: Article

References (29)

1. Horning, S. J. (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol, 20, pp. 75-88.
2. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A. and Metzner, B. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, pp. 3064-3071.
3. Herold, M., Haas, A., Srock, S., Neser, S., Al-Aki, K. H. and Neubauer, A. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol, 25, pp. 1986-1992.
4. Horning, S. J. (2000) Follicular lymphoma: Have we made any progress?. Ann Oncol, 11, pp. 23-27.
5. Lister, T. A. (1991) The management of follicular lymphoma. Ann Oncol, 2, pp. 131-135.
6. Rambaldi, A., Lazzari, M., Manzoni, C., Carlotti, E., Arcaini, L. and Baccarani (2002) Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood, 99, pp. 856-862.
7. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S. and Williams, M. E. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol, 16, pp. 2825-2833.
8. Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P. and Delwail, V. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood, 97, pp. 101-106.
9. Economopoulos, T., Fountzilas, G., Pavlidis, N., Kalantzis, D., Papageorgiou, E. and Christodoulou, C. (2003) Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Hematol J, 4, pp. 110-115.
10. Czuczman, M. S., Grillo-Lopez, A. J., White, C. A., Saleh, M., Gordon, L. and LoBuglio, A. F. (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol, 17, pp. 268-276.
11. Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S. and Link, B. K. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol, 18, pp. 3135-3143.
12. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E. and Schmits, R. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, pp. 3725-3732.
13. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E. and Catalano, J. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, pp. 1417-1423.
14. Herold, M., Dolken, G., Fiedler, F., Franke, A., Freund, M. and Helbig, W. (2003) Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol, 82, pp. 77-79.
15. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U. and Metzner, B. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol, 23, pp. 1984-1992.
16. Schulz, H., Skoetz, N., Bohlius, J., Treller, S., Kober, T. and Greb, A. (2005) Does combined immunochemotherapy with the monoclonal antibody rituximab improve overall survival in the treatment of patients with indolent non-Hodgkin lymphoma? Preliminary results of a comprehensive meta-analysis. Blood, p. 350.
17. Schmitt, C., Grundt, A., Buchholtz, C., Scheuer, L., Benner, A. and Hensel, M. (2006) One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?. Leuk Res, 30, pp. 1563-1568.
18. Dimopoulos, M. A., Fountzilas, G., Papageorgiou, E., Kiamouris, C., Mantzios, G. and Anagnostopoulos, A. (2002) Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: A phase II study of the Hellenic Cooperative Oncology Group. Leuk Lymphoma, 43, pp. 111-114.
19. Seymour, J. F., Grigg, A. P., Szer, J. and Fox, R. M. (2001) Fludarabine and mitoxantrone: Effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol, 12, pp. 1455-1460.
20. Zinzani, P. L., Magagnoli, M., Bendandi, M., Gherlinzoni, F., Orcioni, G. F. and Cellini, C. (2000) Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol, 11, pp. 363-365.
21. Zinzani, P. L., Pulsoni, A., Perrotti, A., Soverini, S., Zaja, F. and De Renzo, A. (2004) Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol, 22, pp. 2654-2661.
22. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
23. Hagemeister, F., Cabanillas, F., Coleman, M., Grecory, S. A. and Zinzani, P. L. (2005) The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist, 10, pp. 150-159.
24. Foussard, C., Colombat, P., Maisonneuve, H., Berthou, C., Gressin, R. and Rousselet, M. C. (2005) Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. Ann Oncol, 16, pp. 466-472.
25. Ghielmini, M., Schmitz, S. F., Cogliatti, S. B., Pichert, G., Hummerjohann, J. and Waltzer, U. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule. Blood, 103, pp. 4416-4423.
26. Hochster, H. S., Weller, E., Gascoyne, R., Teodorovic, I., Rosewics, C. and Klasa, R. (2005) Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood, p. 353.
27. Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Grimaldi, M. and Greco, F. A. (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol, 23, pp. 1088-1095.
28. van Oers, M. H., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E. and Gascoyne, R. D. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood, 108, pp. 3295-3301.
29. Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H. P., Repp, R. and Wandt, H. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 108, pp. 4003-4008.